{"id":"W2978186977","doi":"10.1093/annonc/mdz240.110","title":"Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Open label; Oncology; Immunotherapy; Neoadjuvant therapy; Internal medicine; Randomized controlled trial; Cancer; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001679388,0.001953512,0.003313334,0.0003313181,0.0004566161,0.001290377,0.0008331204,0.001540702,0.006787087],"category_scores_gemma":[0.001083899,0.0006707521,0.001986797,0.0004223518,0.001679143,0.00177444,0.0006000126,0.003882731,0.00139763],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001052359,"about_ca_system_score_gemma":0.001304304,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006441833,"about_ca_topic_score_gemma":0.001662124,"domain_scores_codex":[0.9994154,0.0002796359,0.00002943217,0.0001237591,0.0000408686,0.0001109779],"domain_scores_gemma":[0.9993302,0.0001785117,0.0001213834,0.00007808557,0.00003015421,0.0002617554],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9692216,0.00873775,0.0003743694,0.0004329448,0.0007271647,0.00002776532,0.00004123856,0.0005220732,0.002537644,0.0001611532,0.0009066979,0.01630955],"study_design_scores_gemma":[0.918786,0.0777628,0.0009392202,0.00003214586,0.0004672705,0.00003067347,0.0000217104,0.0003547757,0.0003803231,0.0002029965,0.001007935,0.00001424134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774441,0.006967779,0.001834882,0.001629847,0.001145142,0.005007473,0.00177442,0.0001749315,0.004021308],"genre_scores_gemma":[0.9695608,0.005727709,0.003436983,0.00237518,0.0006825537,0.009474703,0.002577325,0.00006095419,0.006103835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006787087,"threshold_uncertainty_score":0.02270508,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09962862780967344,"score_gpt":0.4323160443553067,"score_spread":0.3326874165456333,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}